CLRB Cellectar Biosciences, Inc.
Healthcare$3.10-3.13%ClosedMarket Cap: $9.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.88
P/S
0.00
EV/EBITDA
-0.15
DCF Value
$4.38
FCF Yield
-182.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-264.8%
ROA
-187.4%
ROIC
-358.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | Infinity% | $-5.8M | $-5.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-5.7M | $-5.3M | $— | — |
| FY null | $0.00 | -Infinity% | $-23.0M | $-21.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.9M | $-4.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.0M | $-5.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.4M | $-6.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-12.7M | $-2.4M | $— | — |
| FY null | $0.00 | NaN% | $-51.8M | $-44.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-13.3M | $-14.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-13.7M | $-919.4K | $— | — |
| Q1 null | $0.00 | NaN% | $-12.0M | $-26.6M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-12.5M | $-7.9M | $-12.17 | — |